ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将评估长期口服阿昔洛韦抑制疗法对仅限于皮肤、眼睛或口腔的新生儿疱疹感染的疗效(扫描电子显微镜)。它将确定口服阿昔洛韦抑制性治疗是否改善了患有SEM病的婴儿的神经学结果。此外，它还将确定持续口服阿昔洛韦混悬液是否能抑制婴儿扫描电子显微镜疾病后复发的皮肤损害。它将证实长期口服阿昔洛韦治疗在一组患有SEM病的婴儿中的安全性。将评估皮肤复发时脑脊液聚合酶链式反应阳性结果的意义，并监测和表征对阿昔洛韦耐药的病毒变异体的发展。最后，将对阿昔洛韦抑制疗法在药物经济学和家庭基础设施问题上的效果进行评估和量化。GCRC通过提供临床空间、护理人员、资助专门的测试和实验室支持来利用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will evaluate the efficacy of long-term suppressive therapy with oral acyclovir in infants with neonatal herpes infections limited to the skin, eye, or mouth (SEM). It will determine if suppressive oral acyclovir therapy improves neurologic outcome in infants following SEM disease. Additionally, it will determine if continuous administration of oral acyclovir suspension suppresses recurrent skin lesions in infants following SEM disease. It will confirm the safety of long-term administration of oral acyclovir therapy in a cohort of infants with SEM disease. The significance of positive CSF PCR results at the time of cutaneous recurrences will be assessed, and the development of viral variants resistant to acyclovir monitored and characterized. Finally, the effects of suppressive acyclovir therapy on issues of pharmocoeconomics and family infrastructure will be assessed and quantitated. The GCRC is utilized by providing clinical space, nursing staff, funding specialized testing and laboratory support.